Fatty acid biosynthesis is catalysed in most bacteria by a group of highly conserved proteins known as the Type I1 fatty acid synthase (FAS) system. The Type I1 system organization is distinct from its mammalian counterpart and offers several unique sites for selective inhibition by antibacterial agents. There has been remarkable progress in the understanding of the genetics, biochemistry and regulation of Type I1 FASs. One important advance is the discovery of the interaction between the fatty acid degradation regulator, FadR, and the fatty acid biosynthesis regulator, FabR, in the transcriptional control of unsaturated fatty acid synthesis in Escherichia coli. The availability of genomic Key words: Streptococcus pneurnoniae, transcriptional regulator, unsaturated fatty acid. Abbreviations used: ACP, acyl carrier protein; AcpM, Mycobacterium tuberculosis ACP; FabA. P-hydroxydecanoyl-ACP dehydrataselisomerase; FabB, P-ketoacyl-ACP synthase I : FabD, rnalonyl-CoA: ACP transacylase; FabF. /3-ketoacyl-ACP synthase 11; FabG. /%ketoacyl-ACP reductase; FabH, P-ketoacyl-ACP synthase 111; Fabl. enoyl-ACP reductase I; FabK. enoyl-ACP reductase 11; FabL. enoyl-ACP reductase 111; FabM, trons-2-cis-3-enoyl-ACP isomerase; FabR, fatty acid biosynthesis regulator; FabZ, phydroxyacyl-ACP dehydratase; FadR, fatty acid degradation regulator; FAS, fatty acid synthase; KasA, j.-ketoacyl-ACP synthase A; KasB, P-ketoacyl-ACP synthase B; PlsB. glycerol 3-phosphate acyltransferase; SFA. saturated fatty acid; UFA, unsaturated fatty acid. sequences and high-resolution protein crystal structures has expanded our understanding of Type I1 FASs beyond the E. coli model system to a number of pathogens. The molecular diversity among the pathway enzymes is illustrated by the discovery of a new type of enoyl-reductase in Streptococcus pneumoniae [enoyl-acyl carrier protein (ACP) reductase 11, FabK], the presence of two enoyl-reductases in Bacillus subtilis (enoyl-ACP reductases I and 111, FabI and FabL), and the uw of a new mechanism for unsaturated fatty acid formation in S. pneumoniae (trans-2-cis-3-enoyl-ACP isomerase, FabM). The solution structure of ACP from Mycobacterium tuberculosis revealed features common to all ACPs, but its extended C-terminal domain may reflect a specific interaction with very-long-chain intermediates.
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Bacterial Type II fatty acid synthesis
The biosynthesis of fatty acids is the first step in the formation of membrane lipids, and represents a vital aspect of bacterial physiology. Most bacteria and plants synthesize fatty acids using a discrete and highly conserved group of enzymes, designated as the Type 11, or dissociated, fatty acid synthase (FAS) system (reviewed in [1, 2] ). This organization differs from the mammalian Type I system, where all the reactions are carried out by a single multifunctional polypeptide.
The research on lipid metabolism has seen remarkable progress since the establishment of the fatty acid biosynthetic pathway in Escherichia coli, which serves as a model for understanding Type I1 systems in other bacteria [I] . All the genes required for fatty acid synthesis in E. coli are known and the enzymes have been biochemically characterized ( Figure 1 and Table 1 ). A key feature of the Type I1 system is that the hydrophobic fatty acyl intermediates are shuttled from enzyme to enzyme by a small, highly acidic acyl carrier protein (ACP). The first enzyme of fatty acid biosynthesis is acetyl-CoA carboxylase, a heterotetrameric enzyme encoded by four genes, accA, accB, accC and accD. The product of the reaction is malonyl-CoA, and the malonate group is transferred to ACP by the malonyl-CoA : ACP transacylase (FabD) to form malonyl-ACP (Figure 1 
Drug discovery and Type II FASs
One of the most important advances in recent years has been the increasing interest in fatty acid biosynthesis as a target for the development of potent antibacterial therapeutics [29] . T h e increasing drug resistance amongst major human pathogens is limiting our ability to effectively treat bacterial infections and new therapeutics, acting via novel mechanisms, are needed. Thus, fatty acid biosynthetic enzymes are attractive targets for drug discovery. T h e availability of crystal structures for most of the biosynthetic enzymes is invaluable for understanding the catalytic mechanism underlying the structural features. T h e cocrystals with known inhibitors provide insight into how the interaction of the enzyme and substrate could be optimized or disrupted to design better inhibitors.
Cerulenin [37, 39] . Although the future of triclosanbased inhibitors seems promising, the recent discovery of enoyl-ACP reductases that are completely refractory to triclosan action [ 101 has shed some doubt on whether these compounds will be developed as broad-spectrum antibacterials. 
